Skip to content

PAR-25-032 NHLBI R34 pilot eligibility Guide

Updated 28 official sources

Quick Answer: PAR-25-032 is NHLBI's R34 for pilot studies that settle open design questions before a Phase II-IV trial in heart, lung, blood, or sleep disorders.

Full answer and how we checked it

It's clinical trial optional and allows up to $450,000 in direct costs over 3 years. The next date is November 16, 2026 for resubmissions. NHLBI added February 16, 2027 (new) and March 16, 2027 (resubmission), and the NOFO now expires March 17, 2027.

Who this is for: Clinical researchers in cardiology, pulmonary and critical care, hematology, transfusion and transplant medicine, and sleep medicine, plus the biostatisticians and research offices behind them, deciding whether an NHLBI pilot R34 is the right step before a full trial application.

Data note: Grantsights checked PAR-25-032 (opens in a new tab), NHLBI's trial pages, and the NIH-wide notices cited below on October 18, 2026, and rechecked the due dates against NOT-HL-27-003 (opens in a new tab) on November 9, 2026. Award figures come from the NIH RePORTER API, pulled October 18, 2026; the method is stated in the analysis section.

In this guide

Quick Facts

Agency
HHS
Deadline
Mar 16, 2027
Status
Open

Assistance Listing 93.838: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.838, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
1,105
Avg Award (whole listing)
$3,682,890
Median Award (whole listing)
$2,367,708
YoY Funding Trend
-98.5%

Data last verified: May 19, 2026

PAR-25-032 isn't a generic planning grant. According to NIH in PAR-25-032 (opens in a new tab), the R34 supports studies that are both necessary and sufficient to inform planning of a future Phase II-IV clinical trial within NHLBI's mission. That trial must primarily test the efficacy, safety, clinical management, or implementation of interventions for heart, lung, blood, or sleep disorders.

So the question for an investigator is narrow: what uncertainty is stopping you from writing the final protocol, and will this pilot remove it? If the trial is already fully designed, the R34 is the wrong path. If the trial question is still vague, it's premature.

Start with the live NHLBI Clinical Trial Pilot R34 program record, and if the NIH vocabulary is new, read what is a NOFO first.

November 2026 Source Check

As of November 9, 2026, PAR-25-032 (opens in a new tab) has 3 due dates left: November 16, 2026 for resubmission (A1) applications, then February 16, 2027 for new applications and March 16, 2027 for resubmissions. NHLBI added the 2027 round on October 20, 2026 in NOT-HL-27-003 (opens in a new tab), which also moved the expiration from January 8, 2027 to March 17, 2027. According to the NIH table, a November 16 resubmission goes to peer review in March 2027 and council in May 2027, with an earliest start of July 2027. The 2027 round goes to review in July 2027 and council in October 2027, with an earliest start of December 2027.

NHLBI extended this NOFO rather than reissuing it. It has reissued the R34 repeatedly before: PAR-25-032 replaced PAR-24-049, and RePORTER shows awards under PAR-10-005, PAR-13-002, PAR-16-037, PAR-18-463, PAR-19-155, and PAR-21-079 before that. A reissue after March 2027 is likely but not announced, so plan new work around February 16, 2027.

Three older facts are now wrong:

  • AIDS dates. NIH removed AIDS application due dates in NOT-OD-26-029 (opens in a new tab), so the September 7, 2026 and January 7, 2027 AIDS dates no longer apply.
  • New applications. October 16, 2026 is no longer the last new-application date. February 16, 2027 is.
  • Resubmission timing. NIH won't accept an A1 before the summary statement from the A0 review is issued, so the November 16 date only works for teams that already have one.

The budget hasn't changed: up to $450,000 in direct costs over a maximum 3-year period, with no more than $225,000 in direct costs in any single year. Only new and resubmission applications are allowed, and all applications are due by 5 p.m. local time of the applicant organization.

7 PAR-25-032 Eligibility Stop Checks

Run these 7 stop checks before anyone starts a Specific Aims page. NHLBI wants a pilot whose results change the design of the later trial, not a scaled-down version of that trial.

Stop checkStrong NHLBI R34 signalRed flag
NHLBI missionHeart, lung, blood, or sleep disorderTreating a malignancy, or outside NHLBI's mission
Future trialPhase II, III, or IV trial written out in 3 pagesFuture trial is a paragraph of intentions
Pilot questionNamed scientific or operational uncertaintyPilot only starts up a known trial
SufficiencyResults finalize the later protocol with no further studiesAnother pilot would still be needed
Product statusNo IND/IDE needed, or a plan to have FDA documentation before fundingIND or IDE path not addressed
Investigator recordBiosketches show clinical trial experienceNo one on the team has run a trial
Route sequenceFull trial planned as a separate applicationR34 treated as trial funding

A common mistake is proposing pilot activities that are useful but not decisive. NHLBI's sufficiency language means reviewers ask whether, at the end of the R34, the team could write the final protocol without another round of preliminary work.

5 Source Facts Applicants Should Know

According to NIH in PAR-25-032 (opens in a new tab), the activity code is R34, the clinical-trial designation is optional, the expiration date is March 17, 2027 (moved from January 8, 2027 by NOT-HL-27-003 (opens in a new tab)), and the NOFO was updated on March 31, 2025 "to align with agency priorities." Applicants who drafted from an older copy should reread the current text.

According to NHLBI's Clinical Trial Development Continuum (opens in a new tab), PAR-25-032 is the pilot step in a ladder that runs from early-phase R61/R33 trials through single-site and multi-site investigator-initiated trials.

FactCurrent NIH read
Funding numberPAR-25-032 (reissue of PAR-24-049)
MechanismR34 planning grant
Clinical trial designationOptional
MissionHeart, lung, blood, or sleep disorders
Budget cap$450,000 direct over 3 years; $225,000 direct maximum in any year
Eligible applicantsU.S. organizations; foreign organizations can't apply, foreign components allowed
Next resubmission dateNovember 16, 2026
Last new-application dateFebruary 16, 2027
Last resubmission dateMarch 16, 2027
ExpirationMarch 17, 2027

Grantsights Analysis of 151 NHLBI R34 Pilot Awards

Grantsights analysis of NIH RePORTER records found 151 new NHLBI clinical trial pilot R34 awards from FY2011 through FY2026, with a median first-year award of $260,597 (direct plus indirect) for FY2021-FY2024 awards and a median total of $721,842 across all years for projects that started FY2016-FY2022.

Method: on October 18, 2026, Grantsights queried the NIH RePORTER API (opens in a new tab) for NHLBI-administered R34 projects in fiscal years 2010 to 2026, kept new (type 1) awards made under the 8 clinical-trial-pilot NOFOs from PAR-10-005 to PAR-25-032, and excluded R34s made under RFAs and other announcements. Amounts are RePORTER's total cost, which includes the institution's indirect costs, and FY2026 records may still be posting.

Fiscal yearNew NHLBI pilot R34sMedian first-year total costNOFO
FY20166$328,177PAR-13-002
FY201716$249,267PAR-16-037
FY201811$339,820PAR-16-037
FY20195$361,688PAR-18-463
FY20206$245,850PAR-18-463, PAR-19-155
FY20217$264,000PAR-19-155
FY20225$215,700PAR-21-079
FY202314$272,644PAR-21-079
FY20246$251,790PAR-21-079
FY202514$328,685PAR-24-049
FY202620$259,688PAR-25-032

Three things stand out. First, volume is small and uneven: 5 to 20 new awards a year, so a single council round may fund only a handful. Second, the FY2026 cohort of 20 is the largest in the series, spread across 17 states. Third, some recent awards were paid up front. For example, one investigator at UMass Chan Medical School, Chinmay Trivedi, received $744,613 in FY2026 for "Trial Readiness for Metformin in Aortic Valve Stenosis," with $450,000 in direct costs on one record, the full 3-year cap. That fits the multiyear funding NIH may do under Section 240 of the FY2026 appropriations act, described in NOT-OD-26-059 (opens in a new tab).

Did the pilots lead to trials? Grantsights matched each R34's principal investigators, by RePORTER profile ID, to later new NHLBI awards that started after the R34 did. Of 92 pilot R34s that started FY2011-FY2021 (so each had at least 5 years to follow):

Follow-on measureR34 projectsShare
A PI later won any new NHLBI R01, U01, R61, UG3, or similar award5661%
A PI later won an NHLBI award under a trial-designated NOFO (title says clinical trial required, or a multi-site or Phase II trial NOFO)2729%
Of those, the trial award was an R01 or U01910%
The later trial award's title clearly continues the R34's intervention1516%

The last row is the honest one. A PI-level match counts any later award, and some are unrelated: one prehospital whole-blood pilot PI was later a PI on an unrelated sickle cell trial, for instance. When Grantsights read the titles of the 27 trial awards, 15 clearly carried the R34's intervention forward. Of those 15, 8 were R61/R33 single-site or early-phase trials, 6 were UG3/UH3 multi-site trials, 1 was an R01, and none was a U01. The median gap from R34 to the trial award was 5 fiscal years.

Real examples from RePORTER:

This measure undercounts. It misses trials funded by other institutes, PCORI, the VA, or industry, and trials led by a different PI. Treat 16% as a floor, not a success rate.

What NHLBI Doesn't Tell You

The NOFO describes what the R34 is; it doesn't describe what happens next. Four points come from reading it next to the award records and NHLBI's other pages.

First, the next step usually isn't an R01. In the analysis above, 14 of the 15 pilots that led to a matching trial went to R61/R33 or UG3/UH3. Plan the R34 so its outputs (effect-size range, event rate, enrollment per site per month) are the numbers those trial NOFOs ask for.

Second, NHLBI's Clinical Trial Development Continuum (opens in a new tab) page still lists PAR-25-028 and PAR-25-029 for single-site and multi-site investigator-initiated trials. The NIH Guide shows their successors: PAR-27-011 (single-site R61/R33) and PAR-27-012 (multi-site UG3/UH3 clinical coordinating center), both released March 18, 2026 and expiring November 3, 2028. Check the NIH Guide, not only NHLBI's page.

Third, the malignancy exclusion is narrower than it sounds. The NOFO says research on preventing or treating malignancies is outside NHLBI's mission. RePORTER shows NHLBI funded Jeffrey Zwicker's FY2016 R34 on thromboprophylaxis for hospitalized cancer patients and Doris Ponce's FY2026 R34 at Sloan Kettering on gut graft-versus-host disease. Pilots on heart, lung, blood, or sleep complications in people with cancer can fit; confirm with program staff.

Fourth, FDA timing can stall an award after a good score. NIH says R34 studies that need an IND or IDE must secure that authorization and document it to NHLBI before a funding decision. If the FDA clock is uncertain, say so in the FDA attachment with dates.

3 Required Attachments and What They Must Contain

PAR-25-032 adds 3 named attachments to the standard NIH R application, and one of them decides whether review happens at all.

AttachmentFilenameRule
Future clinical trial descriptionFuture Clinical Trial Description.pdfRequired, 3 pages maximum. Describes the later Phase II-IV trial, not the R34 pilot. Without it the application is incomplete and isn't reviewed
FDA statusFDA Approval.pdfIf the R34 needs FDA review, include the approval, or the plan, timeline, and status for getting it
AgreementsSupporting Documents.pdfRelevant contracts, MOUs, or agreements, combined into one file

The future trial description is easy to get wrong. NIH says it should give context for the R34 and shouldn't describe any pilot trial run during the R34 period. Applications fail because teams paste the R34 aims into those 3 pages instead of the later trial's design.

The Research Strategy carries 4 more NOFO-specific instructions: show how R34 results lead to decisions about the future trial, explain why the data are both necessary and sufficient for those decisions, address the health problem the future trial targets, and give evidence of a Data Management and Sharing Plan, a statistical analysis plan, and biostatistical support. The Facilities section should show each site's capacity to recruit the required number of participants.

6 Project Types NHLBI Rules Out

The NOFO names 6 project types that aren't appropriate for this R34. Each one points to a different route.

Not appropriate for PAR-25-032What to do instead
First-in-human studyNHLBI early-phase R61/R33 (PAR-25-026, expires February 4, 2027)
Implementing an already designed trialSingle-site R61/R33 (PAR-27-011) or multi-site UG3/UH3 (PAR-27-012)
Purely mechanistic researchA research project grant; NHLBI accepts mechanistic trials only through the Parent R01 Clinical Trial Required
Writing a protocol or manualNot funded under this NOFO
Developing infrastructureNot funded under this NOFO
Animal studiesNot funded under this NOFO

NHLBI lists its trial opportunities on its clinical trials funding page (opens in a new tab). The NOFO gives examples of work that does fit: refining the population, consent process, statistical methods, intervention, or outcome; verifying available populations, attrition, event, or response rates; standardizing an intervention or outcome across sites; testing whether adherence is achievable; validating survey instruments; testing training tools; and adapting an intervention for a culturally different population.

How Reviewers Read an R34

PAR-25-032 uses the simplified review framework NIH applied to most research grants from January 25, 2025. According to NIH in NOT-OD-24-010 (opens in a new tab), Factor 1 (Importance of the Research) and Factor 2 (Rigor and Feasibility) are each scored 1 to 9, while Factor 3 (Expertise and Resources) gets no score: reviewers mark it appropriate or flag specific gaps.

For a pilot, Factor 2 is where applications are won or lost. The NOFO asks reviewers to judge 3 things that pilot applications often leave thin: whether the plan can recruit and retain the participants it needs, whether the proposed enrollment is achievable, and whether the study timeline and milestones are feasible. A recruitment table built from real clinic counts at each site answers the first 2 better than a sentence saying recruitment will be easy.

Only applications judged to have the highest merit, generally the top half, are discussed and get an overall impact score. NHLBI also asks for, but doesn't require, a letter of intent to its Office of Scientific Review; it doesn't bind the applicant and helps NHLBI plan review. For how to read the critiques that come back, see how to read your NIH summary statement.

NIH-Wide Changes Since 2025 That Reach This R34

At least 4 NIH-wide changes from 2025 and 2026 affect an NHLBI R34 resubmission.

ChangeWhat it means for a PAR-25-032 applicantSource
Unified Funding StrategySince the January 2026 council round, institutes "will not rely on funding paylines"; scores are weighed with priorities, strategic plans, and budgetsNIH Extramural Nexus, November 21, 2025 (opens in a new tab)
Indirect costsThe 15% cap in NOT-OD-25-068 isn't in effect; budget at your negotiated rateNOT-OD-26-060 (opens in a new tab)
Common FormsBiosketch and Current and Pending (Other) Support Common Forms, made in SciENcv, required for due dates on or after May 8, 2026NOT-OD-26-079 (opens in a new tab)
Application limitNo more than 6 new, renewal, resubmission, or revision applications per PI per calendar yearNOT-OD-25-132 (opens in a new tab)

Funding decisions without a payline. According to NIH's November 21, 2025 Unified Funding Strategy post, around half of NIH institutes used to set paylines. A March 2027 score won't be compared against a published NHLBI cutoff, so the program officer conversation after review matters more. Older payline figures are in the NHLBI payline guide; read them as history.

Indirect costs. In February 2025, NIH announced a flat 15% indirect rate in NOT-OD-25-068 (opens in a new tab). A federal district court in Massachusetts blocked it, and the First Circuit affirmed on January 5, 2026 in Massachusetts v. NIH, No. 25-1343, according to a Venable LLP summary (opens in a new tab). Section 224 of the FY2026 appropriations act, quoted in NOT-OD-26-060, requires NIH to apply indirect-cost rules as they stood in the third quarter of FY2017. According to NOT-OD-26-131 (opens in a new tab), NIH is operating under a continuing resolution at FY2026 levels through December 11, 2026. The R34 cap is on direct costs, so indirect costs sit on top of the $450,000.

Common Forms. NIH adopted the Common Forms in NOT-OD-26-018 (opens in a new tab), then ran a leniency period that ended May 7, 2026. The NOFO asks investigators to show clinical trial experience in their biosketches, which now means the SciENcv Common Form plus the NIH Biographical Sketch Supplement. The NIH biosketch guide covers the new format.

Six applications a year. NOT-OD-25-132 took effect with the September 25, 2025 receipt date and covers every activity code except T awards and R13 conference grants. A November 16 resubmission counts toward that limit, as does every other application listing the same person as PI or multiple PI.

6 Evidence Assets That Make This R34 Stronger

Build 6 evidence assets before drafting. Asset 1 is a future-trial one-pager: phase, disorder, intervention, comparator, setting, population, primary endpoint, and the clinical management or implementation question. It becomes the 3-page Future Clinical Trial Description.

Asset 2 is the pilot decision table. For each uncertainty, list what the R34 will measure, the threshold that changes the trial design, and what the team will do if the threshold is missed. Reviewers reading for sufficiency look for this table.

Asset 3 is an operational feasibility plan: screening-to-enrollment ratios by site, retention, adherence, site workflow, training, remote data capture, event rate, and missing-data risk.

Asset 4 is the regulatory plan. If an IND or IDE is involved, state the submission date, the expected FDA response, and what goes in the FDA Approval attachment.

Asset 5 is the statistical and data plan. The NOFO asks for evidence of a statistical analysis plan and biostatistical support, and NHLBI expects pilot results to be published for the field.

Asset 6 is the later-route map. Name the follow-on NOFO, usually single-site R61/R33 or multi-site UG3/UH3, and check that the R34 outputs match what that NOFO asks for.

5 Route Choices Before Drafting

Compare 5 routes before committing to an R34, especially now that the remaining PAR-25-032 date is for resubmissions only.

NHLBI or NIH routeUse it when...Reason
PAR-25-032 R34 (or its reissue)A pilot answer changes the Phase II-IV trial designThe route fits
PAR-27-011 R61/R33 single-site trialThe trial is ready and runs at one siteThe R61 phase covers start-up
PAR-27-012 UG3/UH3 multi-site trialThe trial is ready and needs several sitesThe UG3 phase covers start-up
PAR-25-026 early-phase R61/R33The product hasn't been tested in humansFirst-in-human work is excluded from the R34
Parent R01 (Clinical Trial Required)The question is mechanistic and the study meets NIH's trial definitionNHLBI routes mechanistic trials here

For an eye or vision study, the NEI clinical research study planning R34 guide covers a different institute with different rules. For how R-series mechanisms compare overall, see NIH R01 R21 R03 K awards comparison, and for phased trial funding, the NHLBI early phase R61/R33 guide.

The strongest R34 has a short answer to "what decision will this pilot change?"

6 Bad-Fit Signals

Watch for 6 bad-fit signals. First, the future trial isn't about heart, lung, blood, or sleep disorders. Second, the work aims to prevent or treat a malignancy. Third, the R34 would be first-in-human.

Fourth, the pilot doesn't answer a scientific or operational uncertainty. Fifth, IND or IDE needs are ignored. Sixth, the team treats the R34 as trial funding rather than a pilot for a later application.

For example, a hypothetical sleep medicine group planning a CPAP adherence trial could fit if the R34 tests recruitment, device-use adherence, and outcome measurement well enough to finalize a Phase III protocol. It wouldn't fit if the team simply wants a smaller effectiveness trial. A real comparison point: Ryan Lee at the University of Virginia received $283,500 in FY2026 (opens in a new tab) for a pilot of a mechanical-power-targeted ventilation strategy in adults on VV ECMO with severe ARDS, a pilot built around one ventilation decision.

21-Day NHLBI R34 Readiness Plan

The 21 days below fit two situations: an A1 team working toward November 16, 2026, and a new-application team working toward February 16, 2027.

Days 1 to 3: confirm the NOFO status in the NIH Guide, the PI's application count under the six-per-year limit, mission fit, and the future trial phase. For an A1, list every summary statement critique by factor.

Days 4 to 7: write or revise the future-trial one-pager and the 3-page Future Clinical Trial Description. Days 8 to 12: build the pilot decision table with thresholds. Days 13 to 16: prepare the regulatory, recruitment, adherence, and data plans, and generate SciENcv Common Forms for every senior/key person.

Days 17 to 21: confirm the follow-on route and send the program-staff note. If the R34 can't settle the future design, pause. NIH's standard due dates (opens in a new tab) are the anchor for any reissue, and a reissued NHLBI R34 would most likely follow them.

5 Things To Bring To NHLBI Program Staff

Bring 5 items to an NHLBI program officer before drafting: the future-trial one-pager, the phase and intervention, the single design decision the pilot will settle, the regulatory status (IND or IDE needs and whether FDA documentation can be in hand before a funding decision), and the recruitment and retention assumptions you plan to test.

For an A1, add the summary statement and a one-paragraph response plan. With no NHLBI payline under the Unified Funding Strategy, program staff are the best read on whether a score is in range.

Finally, show who's funded similar work. NIH RePORTER (opens in a new tab) lists funded R34 projects with titles, institutions, and award amounts. A search for NHLBI R34 awards under PAR-25-032 returns the 20 FY2026 pilots, including Ervin Fox's $333,250 award (opens in a new tab) at the University of Mississippi Medical Center to adapt a home blood pressure monitoring program for rural Mississippi. For background on the wider system, the NIH grants complete guide and NIH new investigator guide cover registrations and early-career rules.

7 Checks Before You Draft

Grantsights checked these 7 items against PAR-25-032 (opens in a new tab), the Grants.gov listing 357800 (opens in a new tab), and the NIH notices cited above on October 18, 2026; the dates were rechecked on November 9, 2026.

NHLBI R34 checkWhat to confirm for PAR-25-032If it fails
DateNovember 16, 2026 (resubmission), February 16, 2027 (new), March 16, 2027 (resubmission); NOFO expires March 17, 2027Watch the NIH Guide for a reissue
A1 eligibilitySummary statement from the A0 already issuedNIH won't accept the A1
Budget$450,000 direct over 3 years; $225,000 direct in any year; F&A at the negotiated rateRebuild the budget before routing
Future trial attachment3 pages, describes the Phase II-IV trial, not the pilotApplication isn't reviewed
Factor 2 evidenceSite-level recruitment, retention, enrollment, and milestone planRigor and Feasibility score suffers
FDAIND/IDE authorization documented before a funding decisionAward waits or doesn't happen
Forms and limitsSciENcv Common Forms; PI under 6 applications this yearSubmission errors or rejection

Final public checklist

  • Confirm the R34 is the right step, or move to PAR-27-011, PAR-27-012, or PAR-25-026.
  • Search the free Grantsights grant database for other heart, lung, blood, and sleep funding.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 1,105 Assistance Listing records | Avg: $3.7M

REAL DATA
1

The General Hospital Corporation

MA

$64.2M
2

National Jewish Health

CO

$53.3M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-032 fund?

It funds pilot studies that answer the scientific or operational questions needed to finalize a future Phase II-IV trial for heart, lung, blood, or sleep disorders. The pilot has to be both necessary and sufficient for those design decisions, and the full trial needs a separate application.

Is PAR-25-032 clinical trial required?

No. The NOFO title is 'NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional).' A pilot can be a small randomized trial or a non-trial feasibility study, but first-in-human work, animal studies, purely mechanistic projects, and implementing an already designed trial are excluded.

What is the next PAR-25-032 due date?

November 16, 2026, for resubmissions. On October 20, 2026, NHLBI added one more round in NOT-HL-27-003: February 16, 2027 for new applications and March 16, 2027 for resubmissions. The NOFO now expires March 17, 2027. NIH removed the AIDS due dates in NOT-OD-26-029.

How much can an NHLBI R34 request?

Up to $450,000 in direct costs over a maximum of 3 years, with no more than $225,000 in direct costs in any single year. Indirect costs are added on top at the institution's negotiated rate; the 15% cap NIH announced in 2025 isn't in effect.

How often does an NHLBI R34 lead to a funded trial?

Grantsights analysis of NIH RePORTER records found that 15 of 92 NHLBI pilot R34s started in FY2011-FY2021 (16%) were followed by an NHLBI trial award to the same PI that continued the same intervention, a median of 5 fiscal years later. Most went through R61/R33 or UG3/UH3, not R01 or U01.

Who should skip this route?

Skip it if the study is first-in-human, aimed at treating a malignancy, outside NHLBI's mission, purely mechanistic, or only start-up work for a trial that's already designed.

Last updated November 9, 2026. Corrected November 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.